In this issue:
Atezolizumab + bevacizumab vs. sunitinib in previously untreated metastatic RCC
Severe immune adverse events with sequential PD-(L)1 blockade and osimertinib
Pembrolizumab vs. chemotherapy in recurrent advanced urothelial cancer
Elective anti-PD-1 discontinuation in advanced melanoma
VEGFR-TKI after immune checkpoint inhibitors for metastatic clear-cell RCC
Immune checkpoint inhibitors with corticosteroids in NSCLC
Pembrolizumab in previously treated advanced cervical cancer
Nivolumab ±ipilimumab in previously treated metastatic urothelial carcinoma
PROSTVAC ineffective in metastatic castration-resistant prostate cancer
Erlotinib ±bevacizumab in EGFR-positive nonsquamous NSCLC
Please login below to download this issue (PDF)